CTTH (CTT Pharmaceutical Holdings) EV-to-OCF: -62.65 (As of Jul. 14, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is CTT Pharmaceutical Holdings EV-to-OCF?

CTT Pharmaceutical Holdings CTTH -0.13% EV-to-OCF is -62.65 as of Jul. 14, 2026. The stock has 4 warning signs investors should review. Among 1,008 Drug Manufacturers companies, CTT Pharmaceutical Holdings ranks better than 94.15% on this metric.

EV-to-OCF is calculated as enterprise value divided by its cash flow from operations. As of today, CTT Pharmaceutical Holdings's Enterprise Value is $4.70 Mil. CTT Pharmaceutical Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.08 Mil. Therefore, CTT Pharmaceutical Holdings's EV-to-OCF for today is -62.65.

The historical rank and industry rank for CTT Pharmaceutical Holdings's EV-to-OCF or its related term are showing as below:

CTTH' s EV-to-OCF Range Over the Past 10 Years
Min: -62.73   Med: 0   Max: -47.95
Current: -62.65

During the past 13 years, the highest EV-to-OCF of CTT Pharmaceutical Holdings was -47.95. The lowest was -62.73. And the median was .

CTTH's EV-to-OCF is ranked better than
94.15% of 1008 companies
in the Drug Manufacturers industry
Industry Median: 10.58 vs CTTH: -62.65

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

As of today (2026-07-14), CTT Pharmaceutical Holdings's stock price is $0.0799. CTT Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.000. Therefore, CTT Pharmaceutical Holdings's PE Ratio (TTM) for today is N/A.


CTT Pharmaceutical Holdings  (OTCPK:CTTH) EV-to-OCF Explanation

EV-to-OCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.

CTT Pharmaceutical Holdings's PE Ratio (TTM) for today is calculated as:

PE Ratio (TTM)=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=0.0799/0.000
=N/A

CTT Pharmaceutical Holdings's share price for today is $0.0799.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CTT Pharmaceutical Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was $0.000.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Cash Flow from Operations is an important financial metric because it represents the cash generated from operating activities at a company's disposal. Companies with a low EV-to-OCF ratio, combined with a strong balance sheet are generally considered as undervalued.


CTT Pharmaceutical Holdings EV-to-OCF Related Terms


CTT Pharmaceutical Holdings EV-to-OCF Historical Data

* Premium members only.

The historical data trend for CTT Pharmaceutical Holdings's EV-to-OCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CTT Pharmaceutical Holdings EV-to-OCF Chart

CTT Pharmaceutical Holdings Annual Data
Trend Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
EV-to-OCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 -132.99 -24.29 -13.54 -47.21

CTT Pharmaceutical Holdings Semi-Annual Data
Dec99 Dec00 Dec01 Dec02 Dec03 Dec04 Dec05 Dec06 Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec24 Dec25
EV-to-OCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 -132.99 -24.29 -13.54 -47.21

CTTH vs BUDZ, SBFM, PRFX: EV-to-OCF Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, CTT Pharmaceutical Holdings's EV-to-OCF, along with its competitors' market caps and EV-to-OCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


CTT Pharmaceutical Holdings EV-to-OCF vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, CTT Pharmaceutical Holdings's EV-to-OCF distribution charts can be found below:

* The bar in red indicates where CTT Pharmaceutical Holdings's EV-to-OCF falls into.



CTT Pharmaceutical Holdings EV-to-OCF Calculation

CTT Pharmaceutical Holdings's EV-to-OCF for today is calculated as:

EV-to-OCF=Enterprise Value (Today)/Cash Flow from Operations (TTM)
=4.699/-0.075
=-62.65

CTT Pharmaceutical Holdings's current Enterprise Value is $4.70 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CTT Pharmaceutical Holdings's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $-0.08 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about EV-to-OCF →
What does a EV-to-OCF of -62.65 mean?
CTT Pharmaceutical Holdings (CTTH) has a EV-to-OCF of -62.65 as of Jul. 14, 2026. According to the industry distribution chart, CTT Pharmaceutical Holdings ranks #59 out of 1008 companies in the Drug Manufacturers industry, placing it in the top 5.9%.
Is CTT Pharmaceutical Holdings' EV-to-OCF too high?
CTT Pharmaceutical Holdings' current EV-to-OCF is -62.65. Based on the distribution chart, CTT Pharmaceutical Holdings ranks #59 out of 1008 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers.
How does CTT Pharmaceutical Holdings' EV-to-OCF compare to BUDZ and SBFM?
According to the Drug Manufacturers industry distribution chart, CTT Pharmaceutical Holdings ranks #59 out of 1008 companies for EV-to-OCF. This places CTT Pharmaceutical Holdings in the top 6% of its industry — outperforming the majority of peers. The industry median EV-to-OCF is 10.58. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-OCF for a Drug Manufacturers company?
The median EV-to-OCF among Drug Manufacturers companies is 10.58, based on 1,008 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-OCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-OCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-OCF mean?
A high EV-to-OCF can signal that a stock is expensive relative to its fundamentals. For the Drug Manufacturers industry, the median EV-to-OCF is 10.58 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CTT Pharmaceutical Holdings's current EV-to-OCF is -62.65. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CTT Pharmaceutical Holdings stock overvalued right now?
CTT Pharmaceutical Holdings (CTTH) has a current EV-to-OCF of -62.65. The current EV-to-OCF is -62.65. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-OCF calculated?
EV-to-OCF is calculated from a company's financial statements. For CTT Pharmaceutical Holdings (CTTH), the current EV-to-OCF is -62.65 as of Jul. 14, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CTT Pharmaceutical Holdings Business Description

Address 3853 Northdale Boulevard, Suite 268, Tampa, FL, USA, 33624
CTT Pharmaceutical Holdings Inc specializes in drug delivery systems technology within the pharmaceutical industry. Its focus is on fast-dissolving drug delivery systems through the development of oral delivery thin wafers. The company's technology platform includes the development of oral delivery thin wafers to deliver treatment as an alternative to smoking and ingestion. This technology platform target both the human and veterinarian(pet) markets for treatment of many diseases. The Company believes that its technology will be one of the first to gain use in majorly markets such as pain management and smoking cessation. The Oral Thin Film formulation is protected by patents in the USA, Canada, Europe and many other countries across the world.